VACCINEXPAR

Equities

VCNX

US9186403013

Real-time Estimate Cboe BZX 11:20:26 2024-03-28 am EDT 5-day change 1st Jan Change
7.55 USD +1.34% Intraday chart for VACCINEXPAR -7.43% -18.34%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Vaccinex, Inc. announced that it expects to receive $1.49961 million in funding CI
Vaccinex, Inc. Announces Chief Financial Officer Changes, Effective March 14, 2024 CI
Vaccinex, Inc. Announces Executive Changes, Effective March 14, 2024 CI
Sector Update: Health Care Stocks Slipping Wednesday Afternoon MT
Vaccinex Shares Rise as Company Announces Eight New Deals for Antibody Discovery Platform MT
Vaccinex, Inc. Announces Multiple New Agreements for Access to ActivMAb Antigen Virus Technology CI
Vaccinex, Inc. announced that it expects to receive $3.700126 million in funding CI
Vaccinex, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Vaccinex, Inc. Reports Clinical Benefit in Interim Analyses from Two Phase 2 Studies of Pepinemab Combination Treatment At Society for Immunotherapy of Cancer's Annual Meeting CI
Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases CI
Top Premarket Gainers MT
Vaccinex Insider Bought Shares Worth $3,000,000, According to a Recent SEC Filing MT
Vaccinex Insider Bought Shares Worth $509,515, According to a Recent SEC Filing MT
Top Midday Decliners MT
Wall Street Set to Open Higher; Personal Consumption Inflation Data Lower Than Expected MT
Top Premarket Decliners MT
Vaccinex Prices Offering of Shares, Warrants for Gross Proceeds of About $9.6 Million MT
Vaccinex's Next Generation ActivMAb®? Technology Published in mAbs CI
Vaccinex, Inc. to Present Update on PDAC/Pepinemab Study CI
Vaccinex Reports Groundbreaking Findings At Medical Conferences Supporting Development of Pepinemab for the Treatment of Neurodegenerative Diseases and Cancer CI
Vaccinex to Implement 1-for-15 Reverse Stock Split MT
Vaccinex, Inc. announced that it has received $0.320002 million in funding from Vaccinex, L.L.C CI
Vaccinex, Inc. announced that it expects to receive $0.5825 million in funding CI
Vaccinex Files Registration Statement for Securities Offering MT
Vaccinex, Inc. announced that it has received $0.65 million in funding CI
Chart VACCINEXPAR
More charts
Vaccinex, Inc. is a clinical-stage biotechnology company. It discovers and develops targeted biotherapeutics to treat diseases with unmet medical needs, including cancer, neurodegenerative diseases and autoimmune disorders. Its platform technologies include SEMA4D antibody platform and ActivMAb antibody discovery platform. SEMA4D antibody platform is the application of its knowledge of SEMA4D biology to develop its lead product candidate pepinemab for the treatment of various diseases and conditions, including cancer and neuroinflammatory and neurodegenerative diseases. Pepinemab's mechanisms of action block the SEMA4D signal and activate innate physiological mechanisms to respond to tumors or tissue injury. ActivMAb antibody discovery platform is a human antibody discovery platform based on a method for expressing multipass membrane proteins, as well as large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface of mammalian pox viruses.
Sector
-
More about the company
  1. Stock
  2. Equities
  3. Stock VACCINEXPAR - Nasdaq
  4. News VACCINEXPAR
  5. Earnings Flash (VCNX) VACCINEX Reports Q3 Revenue $50,000